Konrad M. Wesselmann

Cross-protection of wildtype and vaccine-derived chikungunya virus antibodies against chikungunya and Mayaro viruses in mice

Abstract The live-attenuated vaccine IXCHIQ against chikungunya virus (CHIKV) was approved in 2023, with its efficacy evaluated using human neutralizing antibody titers as surrogate effectiveness criterion. Previous in vivo studies assessed its efficacy at high CHIKV-specific ant...